Engineering of the Fc Region for Improved PK (FcRn Interaction)
- 3.4k Downloads
Interaction of antibodies with the neonatal FcRn receptor controls largely the length of their life cycle. Altering the serum persistence of antibodies through modulation of their interaction with the FcRn may be advantageous for achieving high contrast images shortly after application of the radiolabeled antibody tracer or more efficient therapy with fewer administrations. This protocol describes the steps required for producing antibodies, antibody fragments or antibody Fc fusion proteins with altered in vivo pharmacokinetics through introduction of specific mutations in the antibody Fc region. Included are also protocols for evaluation of binding to the FcRn in vitro and determination of serum half-life through radioiodinating the antibody Fc variants and performing biodistribution studies in mice.
KeywordsSurface Plasmon Resonance Antibody Fragment Dose Calibrator FcRn Binding Immobilization Level
- Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26:78–83PubMedGoogle Scholar
- Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM (2005) Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65:622–631PubMedGoogle Scholar
- Meier W, Gill A, Rogge M, Dabora R, Majeau GR, Oleson FB, Jones WE, Frazier D, Miatkowski K, Hochman PS (1995) Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 2:159–171PubMedGoogle Scholar
- Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC (2006) Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 18:1759–1769PubMedCrossRefGoogle Scholar